Disney Illusion Island Now Available on Nintendo Switch™
28.7.2023 15:00:00 EEST | Business Wire | Press release
Today, Disney Games, in collaboration with developer Dlala Studios, launch Disney Illusion Island globally, a local cooperative 2D platform adventure video game for up to four players, exclusively for Nintendo Switch™.
Experience a brand-new adventure as players join Mickey Mouse, Minnie Mouse, Donald Duck and Goofy on a whimsical journey through the island of Monoth. Explore this beautiful yet mysterious world to recover the three magical Tomes – powerful books used to protect the island. Disney Illusion Island gives players the chance to be a part of an authentic Mickey & Friends adventure with an original story, stunning hand-drawn animation, and an original fully orchestrated score by Ivor Novello and BAFTA-nominated composer Dave Housden.
Watch the Disney Illusion Island Launch Trailer Here.
“Disney Illusion Island marks Mickey Mouse’s return to video games and we’re honored to bring this one-of-a-kind adventure to the Nintendo Switch,” said Luigi Priore, VP, Disney, Pixar and 20th Century Games. “We’re excited to see gamers jump in and explore the wonderfully hand-crafted world of Monoth with their friends and family.”
Featuring the authentic voice actors of Mickey, Minnie, Donald, and Goofy, Disney Illusion Island brings everyone together. Whether playing solo or teaming with up to three friends in local co-op, players will perform high flying platforming feats, uncover secrets, and take on epic boss encounters. There is always something new to discover in the expansive world of Monoth as players uncover the mystery of the stolen Tomes.
“Disney Illusion Island has been an absolute career high for myself and the studio,” said Aj Grand-Scrutton, Creative Director/CEO, Dlala Studios. “We have absolutely loved bringing Mickey, Minnie, Donald and Goofy back in a brand-new 2D platforming adventure and we can’t wait for players to join us in the world of Monoth!”
Disney Illusion Island is now available for $39.99, exclusively for Nintendo Switch on the Nintendo eShop and at retail, beginning today.
For more information about Disney Illusion Island: www.disneyillusionisland.com
For more updates on Disney Illusion Island, please follow us on social below:
About Disney Consumer Products, Games, and Publishing
Consumer Products, Games and Publishing (CPGP) is the division of Disney Parks, Experiences, and Products (DPEP) that brings beloved brands and franchises into the daily lives of families and fans through products – from toys to t-shirts, apps, books, console games and more – and experiences that can be found around the world, including on the shopDisney e-commerce platform and at Disney Parks, as well as local and international retailers. The business is home to world-class teams of product, licensing and retail experts, artists and storytellers, and technologists who inspire imaginations around the world.
About Dlala Studios
Dlala Studios are the creators of Disney Illusion Island and Battletoads (2020). They have also provided work for multiple award-winning titles, such as Sea of Thieves. The Essex-based studio has earned a reputation as an industry leader in 2D animation and for their unique, humorous narrative. The studio celebrated their 10th anniversary in 2022, growing to nearly 40 full-time employees.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230728085491/en/
Contact information
MEDIA CONTACTS
Dylan Quintero
Communications Manager
DYLAN.QUINTERO@DISNEY.COM
Melissa Lee
Senior Specialist, Communications
MELISSA.Y.LEE@DISNEY.COM
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom